Fever-Tree has reported its strongest financial year to date, with revenue rising 14% to £402 million in 2025, driven primarily by the enduring global love affair with gin and tonic. The premium mixer company, which has become as synonymous with the gin renaissance as any distiller, told investors this week that its Indian Tonic Water and Mediterranean Tonic Water ranges — both overwhelmingly consumed with gin — accounted for 62% of total sales, with growth strongest in continental Europe and the United States.
The results, announced at a press briefing in the company's Battersea offices, paint a picture of a business that has successfully navigated the transition from high-growth disruptor to established market leader — no small feat in a consumer goods landscape littered with brands that burned bright and faded fast.
The Details
Fever-Tree's European performance was the headline. Revenue across the continent (excluding the UK) grew by 22%, reaching £128 million. Spain remains the company's largest European market, reflecting that country's deep-rooted gin-tonic culture, but the fastest growth came from Germany (up 31%), Italy (up 28%), and France (up 24%) — markets where gin and tonic consumption is still building from a relatively low base.
"Southern Europe has been drinking gin and tonic for years, but what we're seeing now is genuine momentum in northern and central Europe," said Tim Warrillow, Fever-Tree's co-founder and CEO. "Germany in particular has surprised us — the market there is evolving rapidly, with consumers moving from standard gin-and-mixer serves to premium gin with premium tonic. It's the same trajectory we saw in the UK five or six years ago."
In the United States, Fever-Tree revenue grew by 18% to £97 million. The US gin market is less mature than the UK's, but Warrillow is bullish on its potential. "The US is a £14 billion spirits market, and gin is still massively under-indexed there relative to vodka and whiskey," he said. "As American consumers discover premium gin, they discover premium tonic. We're investing heavily in US distribution and on-trade presence."
The UK, Fever-Tree's home market and largest by revenue, grew more modestly at 8%, reaching £142 million. Warrillow attributed this to market maturity rather than any weakening of demand. "The UK is a sophisticated gin market — consumers here already understand the importance of a quality tonic. Our growth now comes from expanding usage occasions and introducing new products."
On the product front, Fever-Tree's Aromatic Tonic Water — developed specifically for more botanical-forward gins — was the fastest-growing product in the range, with sales up 45% year-on-year. The company also launched a Blood Orange Tonic late in 2025, which has performed ahead of internal expectations.
Industry Context
Fever-Tree's results are significant not just for the company itself but for what they reveal about the state of the gin market. The mixer category is, in effect, a proxy for gin consumption — and the continued growth of premium tonic sales confirms that the premiumisation trend in gin extends to the full serve, not just the spirit.
"You cannot separate the gin story from the tonic story," said Dawn Davies MW, Head Buyer at The Whisky Exchange. "Fever-Tree didn't just ride the gin wave — it helped create it. By convincing consumers that the mixer mattered, they elevated the entire category. A £35 bottle of gin deserves a decent tonic, and once you've made that mental leap, you don't go back to supermarket own-brand."
The competitive landscape in premium mixers has intensified. Brands like Franklin & Sons, East Imperial, and Fentimans have all grown their market share, while Schweppes has launched its own premium 1783 range. But Fever-Tree retains a commanding lead, with an estimated 42% share of the global premium tonic market.
For gin producers, Fever-Tree's growth is largely positive news — a rising tonic tide suggests continued consumer interest in gin serves. But there is a subtler dynamic at play. Several craft gin founders I spoke to expressed mild frustration that Fever-Tree, as a mixer brand, captures a significant share of the value in every gin and tonic sold, while bearing none of the production complexity or regulatory burden of spirits manufacturing.
"Fever-Tree's margins are better than ours, and they don't have to deal with HMRC duty stamps," one Scottish distiller told me, only half-joking. "There's a reason their market cap is £3 billion and most gin brands are valued in the low millions."
What's Next
Fever-Tree has signalled several strategic priorities for 2026. First, continued US expansion, including a new distribution partnership that Warrillow declined to name but described as "transformational." Second, product innovation focused on lower-sugar and no-sugar tonics, responding to consumer demand for healthier options without compromising on taste. Third, investment in the on-trade — specifically, working with bars and restaurants to improve the quality of gin-and-tonic serves.
"Too many bars still serve gin and tonic badly," Warrillow said, with the quiet intensity of a man who has built a business on this conviction. "Wrong glass, wrong ice, wrong proportion, wrong garnish. Every bad G&T is a missed opportunity — for the bar, for the gin brand, and for us."
The company is also exploring the non-alcoholic spirits space, with a range of mixers designed specifically for zero-proof gin alternatives. Given the growth trajectory of the no-and-low category, this could prove prescient.
For the gin industry, Fever-Tree's record results are a reassuring signal. As long as consumers are buying more premium tonic, they are buying more premium gin. The symbiosis that has defined the past decade of the gin renaissance shows no sign of breaking.
